lamivudine (LAM) (100 mg/day	adefovir (ADV) (10 mg/day)	HBeAg levels	11589	11759	As described in Figure 2, HBeAg levels in the LAM + ADV group were 1.81±1.01, 1.52±0.86, 1.26±0.93, and 0.71±0.93 at weeks 12, 24, 52, and 104 of treatment, respectively.
lamivudine (LAM) (100 mg/day	adefovir (ADV) (10 mg/day)	HBeAg levels	11894	12047	There were no statistically significant differences between these 2 groups (P=0.668, 0.729, 0.614, and 0.955 at weeks 12, 24, 52, and 104, respectively).
lamivudine (LAM) (100 mg/day	adefovir (ADV) (10 mg/day)	HBeAg levels	11760	12047	In the ETV group, the levels of HBeAg were 1.66±0.99, 1.43±0.92, 1.12±0.91, and 0.69±0.83 at weeks 12, 24, 52, and 104, respectively. There were no statistically significant differences between these 2 groups (P=0.668, 0.729, 0.614, and 0.955 at weeks 12, 24, 52, and 104, respectively).
